Press releases

Diabetics and other complex patients see strong results with TAXUS stents

Company plans to appeal the judgment of the Delaware U.S. District Court

Details currently confidential; will become public when the European Commission announces its decision

ISS report notes the "compelling strategic rationale" for the combination of companies

Results of the study were published in today's edition of JAMA

Six-month results are consistent with ARRIVE I data

Complex insulin-treated diabetic population shows numerical trend toward improved MACE outcomes with TAXUS versus Cypher

TAXUS trials continue to deliver positive outcomes in complex cases

Team will lead CRM Group following acquisition of Guidant

Completes Company's application for FDA approval